381 related articles for article (PubMed ID: 34196656)
1. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
[TBL] [Abstract][Full Text] [Related]
2. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
Vokinger KN; Hwang TJ; Carl DL; Laube Y; Ludwig WD; Naci H; Kesselheim AS
Lancet Oncol; 2022 Apr; 23(4):514-520. PubMed ID: 35271804
[TBL] [Abstract][Full Text] [Related]
3. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
[TBL] [Abstract][Full Text] [Related]
4. Launch and Post-Launch Prices of Injectable Cancer Drugs in the US: Clinical Benefit, Innovation, Epidemiology, and Competition.
Michaeli DT; Michaeli T
Pharmacoeconomics; 2024 Jan; 42(1):117-131. PubMed ID: 37855850
[TBL] [Abstract][Full Text] [Related]
5. Trends in the costs of drugs launched in the UK between 1981 and 2015: an analysis of the launch price of drugs in five disease areas.
Ward DJ; Doos L; Stevens A
BMJ Open; 2019 May; 9(5):e027625. PubMed ID: 31061053
[TBL] [Abstract][Full Text] [Related]
6. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study.
Vogler S; Vitry A; Babar ZU
Lancet Oncol; 2016 Jan; 17(1):39-47. PubMed ID: 26670089
[TBL] [Abstract][Full Text] [Related]
7. Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In Germany.
Lauenroth VD; Kesselheim AS; Sarpatwari A; Stern AD
Health Aff (Millwood); 2020 Jul; 39(7):1185-1193. PubMed ID: 32634355
[TBL] [Abstract][Full Text] [Related]
8. Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland.
Michaeli DT; Mills M; Kanavos P
Appl Health Econ Health Policy; 2022 Sep; 20(5):757-768. PubMed ID: 35821360
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.
Vivot A; Jacot J; Zeitoun JD; Ravaud P; Crequit P; Porcher R
Ann Oncol; 2017 May; 28(5):1111-1116. PubMed ID: 28453694
[TBL] [Abstract][Full Text] [Related]
10. Trajectories of Injectable Cancer Drug Costs After Launch in the United States.
Gordon N; Stemmer SM; Greenberg D; Goldstein DA
J Clin Oncol; 2018 Feb; 36(4):319-325. PubMed ID: 29016226
[TBL] [Abstract][Full Text] [Related]
11. The use of 'added benefit' to determine the price of new anti-cancer drugs in France, 2004-2017.
Rodwin MA; Mancini J; Duran S; Jalbert AC; Viens P; Maraninchi D; Gonçalves A; Marino P
Eur J Cancer; 2021 Mar; 145():11-18. PubMed ID: 33412466
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland.
Carl DL; Laube Y; Serra-Burriel M; Naci H; Ludwig WD; Vokinger KN
JAMA Netw Open; 2022 Dec; 5(12):e2244670. PubMed ID: 36459139
[TBL] [Abstract][Full Text] [Related]
13. Steady Increase In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure.
Bennette CS; Richards C; Sullivan SD; Ramsey SD
Health Aff (Millwood); 2016 May; 35(5):805-12. PubMed ID: 27140986
[TBL] [Abstract][Full Text] [Related]
14. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
15. International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility.
Jung JH; Kim DJ; Suh K; You J; Lee JH; Joung KI; Suh DC
Int J Environ Res Public Health; 2021 Jan; 18(2):. PubMed ID: 33466893
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Price Index Methods and Drug Price Inflation Estimates for Hepatitis C Virus Medications.
Mattingly TJ; Anderson GF; Levy JF
JAMA Health Forum; 2023 Jun; 4(6):e231317. PubMed ID: 37294584
[TBL] [Abstract][Full Text] [Related]
17. Effects of regulation on drug launch and pricing in interdependent markets.
Danzon PM; Epstein AJ
Adv Health Econ Health Serv Res; 2012; 23():35-71. PubMed ID: 23156660
[TBL] [Abstract][Full Text] [Related]
18. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy.
Trotta F; Mayer F; Barone-Adesi F; Esposito I; Punreddy R; Da Cas R; Traversa G; Perrone F; Martini N; Gyawali B; Addis A
BMJ Open; 2019 Dec; 9(12):e033728. PubMed ID: 31826897
[TBL] [Abstract][Full Text] [Related]
19. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
Mansfield SJ
Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
[TBL] [Abstract][Full Text] [Related]
20. Pricing appraisal of anti-cancer drugs in the South East Asian, Western Pacific and East Mediterranean Region.
Salmasi S; Lee KS; Ming LC; Neoh CF; Elrggal ME; Babar ZD; Khan TM; Hadi MA
BMC Cancer; 2017 Dec; 17(1):903. PubMed ID: 29282008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
